Fig. 3: Association between progression-free survival, overall survival and ctDNA level at baseline. | Communications Medicine

Fig. 3: Association between progression-free survival, overall survival and ctDNA level at baseline.

From: Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

Fig. 3

a Association between progression-free survival and ctDNA level at baseline. b Association between overall survival and ctDNA level at baseline High versus low ctDNA level at inclusion was defined using a cut-off of 1.1 ng/mL HR hazard ratio.

Back to article page